- Home
- SKIL vs ATYR Comparison
SKIL vs ATYR Comparison
Compare SKIL & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIL
- ATYR
- Stock Information
- Founded
- SKIL 1998
- ATYR 2005
- Country
- SKIL United States
- ATYR United States
- Employees
- SKIL N/A
- ATYR N/A
- Industry
- SKIL Computer Software: Prepackaged Software
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKIL Technology
- ATYR Health Care
- Exchange
- SKIL Nasdaq
- ATYR Nasdaq
- Market Cap
- SKIL 174.6M
- ATYR 330.7M
- IPO Year
- SKIL N/A
- ATYR 2015
- Fundamental
- Price
- SKIL $18.81
- ATYR $3.55
- Analyst Decision
- SKIL Buy
- ATYR Strong Buy
- Analyst Count
- SKIL 3
- ATYR 6
- Target Price
- SKIL $35.00
- ATYR $18.60
- AVG Volume (30 Days)
- SKIL 33.4K
- ATYR 1.9M
- Earning Date
- SKIL 04-14-2025
- ATYR 05-01-2025
- Dividend Yield
- SKIL N/A
- ATYR N/A
- EPS Growth
- SKIL N/A
- ATYR N/A
- EPS
- SKIL N/A
- ATYR N/A
- Revenue
- SKIL $534,780,999.00
- ATYR $235,000.00
- Revenue This Year
- SKIL N/A
- ATYR N/A
- Revenue Next Year
- SKIL $5.19
- ATYR $1,752.15
- P/E Ratio
- SKIL N/A
- ATYR N/A
- Revenue Growth
- SKIL N/A
- ATYR N/A
- 52 Week Low
- SKIL $5.09
- ATYR $1.42
- 52 Week High
- SKIL $34.43
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- SKIL 22.73
- ATYR 50.10
- Support Level
- SKIL $17.47
- ATYR $2.98
- Resistance Level
- SKIL $26.28
- ATYR $3.73
- Average True Range (ATR)
- SKIL 1.64
- ATYR 0.39
- MACD
- SKIL -0.90
- ATYR -0.05
- Stochastic Oscillator
- SKIL 12.74
- ATYR 43.22
About SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segment includes Content & Platform and Instructor-Led Training. The Content & Platform business engages in the sale, marketing and delivery of its content learning solutions, in areas such as Leadership and Business, Technology and Developer and Compliance. The Instructor-Led Training business offers training solutions covering information technology and business skills for corporations and their employees. The majority of revenue is from the Content & Platform segment.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.